What’s News in Markets: Walmart Slumps, Omnicom Rallies, Moderna Comeback
WSJ What’s News
February 21, 2026
Why did Walmart fall on strong earnings? And how are Omnicom’s big cost cuts boosting its stock? Plus, will a major FDA reversal change Moderna’s fortunes? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Hosted by Simplecast, an AdsWizz company.
Speakers Jack Pitcher
TopicsDaily NewsNews
SPEAKER_1 (0:00)
This episode is sponsored by Morgan Stanley's Thoughts on the Market. Today's financial markets move fast. Morgan Stanley moves faster with their daily podcast Thoughts on the Market. Thoughts on the Market covers daily trends across the global investment landscape with actionable insights from Morgan Stanley's leading economists and strategists. And with most episodes under five minutes long, staying informed has never been easier. Listen and subscribe to Thoughts on the Market wherever you get your podcasts.
Jack Pitcher (0:32)
Hey, listeners. It's Saturday, February 21st. I'm Jack Pitcher for The Wall Street Journal. And this is What's News in Markets, our look at the biggest stock moves of the week and the news that drove them. Let's get to it. Stocks were relatively muted for the shorter holiday week, but there was no shortage of action under the surface thanks to a big slate of corporate earnings. Investors seem to be regaining some confidence in tech and growth stocks, both of which have sold off for much of the year, over fears that rapid advancements in AI are going to render some software companies obsolete. But this week, communication services and information technology were the S&P 500's best performing sectors. Meanwhile, consumer staples companies, which are often seen as a safe haven, have dropped sharply. That signals a rotation away from the fear trade and back into other parts of the market. Then of course yesterday, the Supreme Court struck down President Trump's sweeping global tariffs. Last April, when they were first announced, the tariffs roiled markets. But a series of deals and carve-outs in the months since helped calm investors' fears. Stocks turned higher after the Supreme Court's decision, but analysts noted the ruling had been largely expected. And Trump said he'd keep the tariffs in place under a different authority. For the week, the S&P 500 rose 1.1 percent while the Dow was 0.3 percent higher. The tech-heavy Nasdaq added 1.5 percent.
Walmart lost a notable crown when it reported earnings on Thursday. After 17 years of being the largest company in the US by annual revenue, the retailer has officially been passed by Amazon. Still, Walmart's quarterly results were actually pretty strong, beating analysts' estimates for sales. Investors were not impressed. In the last three years, Walmart shares have risen around 500% thanks to remarkable results. And that's made the stock expensive by traditional valuation metrics, which leaves it susceptible to disappointment if forecasts are anything less than stellar. Walmart CFO John David Rainey told investors on Thursday that the company is giving conservative guidance because the economic backdrop is somewhat unstable. Walmart shares were among the S&P's worst performers this week, dropping 8%. Investors found more to like with Omnicom's earnings, but employees there may be feeling jittery. Omnicom is the biggest marketing services and advertising conglomerate in the US., and it told investors it was doubling its cost cut target following its acquisition of competitor IPG. It expects to cut $900 million in costs this year, primarily by reducing headcount. Investors cheered the news, sending Omnicom shares up 15% on Thursday and 21% for the week, making them the S&P's best performer. The vaccine maker Moderna has been reeling in the years since sales of its COVID-19 vaccine peaked, and the vaccine skepticism of Health and Human Services Secretary Robert F. Kennedy Jr. has been hitting its shares more recently. But a major reversal from the Food and Drug Administration on Wednesday helped turn sentiment around. Last week, the FDA said it would not review Moderna's application for a new seasonal flu shot. The decision shocked investors, but the regulator has since had a change of heart, saying it will begin review of the new shot after Moderna agreed to additional testing in the elderly. Moderna shares rallied 6% on Wednesday and 18% on the week, putting them among the best performers in the S&P. And now you know What's News in Markets this week. You can read about more stocks that moved on the week's news in our live markets coverage on wsj.com. Today's show was produced by Alexis Moore with Deputy Editor Chris Sensley. I'm Jack Pitcher. Have a great weekend.
SPEAKER_3 (4:40)
Every business is asking the same question. How do we make AI work for us? No more waiting. With NetSuite by Oracle, you can put AI to work today. NetSuite is the number one AI cloud ERP, trusted by over 43,000 businesses. It's the unified suite that brings your financials, inventory, commerce, HR and CRM into a single source of truth. That connected data is what makes your AI smarter, helping you make fast decisions. If your revenue is at least in the seven figures, get our free business guide, Demystifying AI at netsuite.com/wallstreet.
Thousands of transcripts fetched by people building searchable podcast archives
Fetch the whole transcript
The demo key returns a sample episode in full, no card needed:
curl -H "x-api-key: pt_demo" \
https://spoken.md/transcripts/1000651996090Markdown with the speakers named, for your notes, your knowledge base, or anything that makes HTTP calls.
From $0.10 per transcript. No subscription. Credits never expire. Prices exclude VAT, added at checkout for EU customers. Not what you expected? Email us within 14 days with 20 or fewer credits used and we refund the pack in full.
Using your own key:
curl -H "x-api-key: YOUR_KEY" \
https://spoken.md/transcripts/1000750780451